These funds allows us to gain an improved understanding of the way the compounds affect illnesses that cause cognition loss.’ ‘ADispell’s unique method of targeting memory loss holds great guarantee as cure for Alzheimer’s disease,’ said Howard Fillit, M.D., Executive Director for the ADDF.’ There are estimated to become more than 5 million individuals in the United States and more than 35 million individuals worldwide experiencing Alzheimer’s disease. SOURCE Alzheimer’s Drug Discovery Foundation.. Action receives FDA notification regarding its embryonic stem cell trials for SMD Advanced Cellular Technology, Inc. Work is on clinical keep pending a currently response from the Company, which it expects within the next few weeks. To build up small molecule drugs designed to halt the progression of cognition loss occurring with Alzheimer’s Disease... Alkermes initiates pivotal clinical development system for treatment of MDD Alkermes plc today announced the initiation of the pivotal clinical development program for ALKS 5461, a once-daily, oral investigational medicine with a novel system of actions for the adjunctive treatment of major depressive disorder . The comprehensive pivotal program, named FORWARD , includes a total of 12 studies, including three primary phase 3 efficacy research and nine supportive studies. The first FORWARD research, analyzing the onset of scientific effect, safety and tolerability of ALKS 5461 in 60 sufferers with MDD approximately, has begun, and the three core efficacy studies are anticipated to begin with in mid 2014.